Opportunities and Priorities for the Office of New Drugs: Optimizing Outcomes

Kelly Close

founder, The diaTribe Foundation president, Close Concerns

Emily Fitts

Senior Manager, Advocacy & Policy, The diaTribe Foundation

Cherise Shockley

Community Manager, The diaTribe Foundation






Thank you immeasurably!

Diabetes Management = Self-Management

People with diabetes spend 24,000 - 110,000 minutes a year making decisions about their diabetes.

People with diabetes spend 15-120 minutes a year with health care professionals





Expand primary and secondary endpoints that affect patient outcomes



Self-management support





Improved medical and psychosocial outcomes




Lower costs to the entire healthcare system




THE MANY FACES OF A 7% A1C

(and an average blood glucose of 154 mg/dl)




"A Big Impact" On Daily Life, Rank Order: Many Differences, but Time in Range is #1 For All






Patients are far from feeling "very successful" (n=3,455)









A cultural shift – seeing time in range, AGP, improving from any base









Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials


Roy W. Beck,¹ Richard M. Bergenstal,² Tonya D. Riddlesworth,¹ Craig Kollman,¹ Zhaomian Li,¹ Adam S. Brown,³ and Kelly L. Close⁴

Diabetes Care 2019;42:400-405 | https://doi.org/10.2337/dc18-1444



Each incremental 5% increase in TIR is associated with clinically significant benefits for type 1 and type 2

5% change in TIR = 1 hour a day



Every 10% increase in TIR = \sim 0.5-0.8% A1C reduction



Policy Recommendations for FDA Office of New Drugs



Expand primary and secondary endpoints that affect patient outcomes



Establish hypoglycemia as a clinically meaningful endpoint and incorporate hypoglycemia the label for therapeutic differentiation purposes



Acknowledge and establish time-in-range as an important complement to A1C



Investigate other endpoints that are meaningful to patients (e.g., weight loss, diabetes distress, fear of hypo)



Policy Recommendations for FDA Office of New Drugs



Expand harmonization across FDA divisions, particularly related to glucose measurement



Assess CGM data and metrics in clinical trials for diabetes therapies



Encourage greater harmonization among clinical, professional, patient, and regulatory adoption of advanced treatments to improve care and patient outcomes



Policy Recommendations for FDA Office of New Drugs



Improve speed and transparency of guidance creation and dissemination process



Create therapeutic labels that are even more clinically-relevant and patient-friendly




Further consider greater focus on prevention; specifically, establishing a prediabetes pathway



At diaTribe, we are committed to improving the lives of people with diabetes and amplifying patient voices.










diaTribe.org/Join



200,000 subscribers 2.3M visitors annually



The diaTribe Foundation

diaTribe.org | diaTribe.org/Foundation



f /diaTribeNews

@diaTribe

contact@diaTribe.org



Kelly Close

WellyClose

@klclose

kelly.close@diaTribe.org

Cherise Shockley

@sweetercherise
 cherise.shockley@diatribe.org

Emily Fitts emily.fitts@diatribe.org

